Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.…
Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function
Veru (NASDAQ: VERU) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 20 employees.
The shares were at 1.940 USD on 20 November 2026, down 23.0% over 52 weeks. Its 52-week range is 1.930 USD to 7.330 USD, and it trades at the bottom of that range.
Its market capitalisation is 33.08M USD.
Veru reports return on equity of -124.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 23.05M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 17 December 2026.